Polycystic ovary syndrome, androgens and menopause

Abstract

Polycystic ovarian syndrome (PCOS) is the most common disorder of the reproductive life, affecting 5-10% of women. The well-documented cardiometabolic manifestations of PCOS are associated with the underlying hyperinsulinemia and the degree of hyperandrogenemia, which are well established in the premenopausal years. A large body of evidence explored whether the cardiovascular risk related to a PCOS diagnosis persists into the postmenopausal years.